Purpose: Sentinel node biopsy (SNB) is routinely performed in patients with clinically node-negative early breast cancer (EBC) undergoing primary surgery to assess the axilla. Though it has no proven therapeutic benefit, nodal status information from SNB helps in prognostication and can influence adjuvant systemic and locoregional treatment choices. However, the redundancy of the nodal status information is becoming increasingly apparent, and hence, a non-invasive alternative to SNB is highly desirable. The Memorial Sloan-Kettering Cancer Center (MSKCC) nomogram predicts the lymph node status based on eight clinicopathological variables. Our study aims to validate this model in an Australian cohort. Methodology: We performed a retrospective analysis of EBC patients presenting to our institution between 2012 and 2020. Data gathered include age, tumour size, lymphovascular invasion (LVI), tumour location, multifocality, histologic type and grade, and Oestrogen and Progesterone receptor (ER & PR) positivity. These clinicopathologic variables were entered into the MSKCC nomogram. The models' receiver operating characteristics (ROC) curve was created, and the area under the curve (AUC) was computed. Results: 1121 patients were eligible for the study. The mean age of the population was 61 years. 16.6 % of all SNB had a positive result. The model's accuracy in predicting the sentinel node status in an individual case is moderate. Conclusion: The MSKCC nomogram is a preoperative tool to support clinical decision-making for patients. This tool was validated in a large cohort of Australian patients.